石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

休市中 05-22 16:08:22

7.690

+0.350

+4.77%

最高7.870	最低7.500	成交量9,941万
今开7.500	昨收7.340	日振幅5.04%
总市值886.04亿	流通市值886.04亿	总股本115.22亿
成交额7.69亿	换手率0.86%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":7.69,"timestamp":1779437302003,"preClose":7.34,"halted":0,"volume":99408690,"delay":0,"changeRate":0.047683923705722144,"floatShares":11522000000,"shares":11522000000,"eps":0.39181270373620863,"marketStatus":"休市中","change":0.35,"latestTime":"05-22 16:08:22","open":7.5,"high":7.87,"low":7.5,"amount":769236334,"amplitude":0.050409,"askPrice":7.69,"askSize":8000,"bidPrice":7.68,"bidSize":98000,"shortable":3,"etf":0,"ttmEps":0.39181270373620863,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779759000000},"marketStatusCode":7,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":7.34,"dividendRate":0.031235,"openAndCloseTimeList":[[1779413400000,1779422400000],[1779426000000,1779436800000]],"volumeRatio":1.425268,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":false,"expireDate":1782662400000,"strike":"7.25","timestamp":1779436482562,"price":0.27,"volume":250,"amount":135000,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.4703,"impliedVolPercentile":0.1579},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2637151312","title":"汇添富基金管理股份有限公司减持石药集团(01093)982.4万股 每股作价约7.45港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637151312","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637151312?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:52","pubTimestamp":1779454335,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月19日，汇添富基金管理股份有限公司减持石药集团(01093)982.4万股，每股作价7.4527港元，总金额约为7321.53万港元。减持后最新持股数目约为5.7亿股，持股比例为4.95%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1152091168.USD","IE00BZ08YT58.USD","LU1813983027.USD","LU0072913022.USD","LU0314109678.HKD","IE00BZ08YS42.EUR","LU0140636845.USD","LU1226288170.HKD","LU1008478684.HKD","HK0000165453.HKD","LU1807302812.USD","LU1226288253.USD","BK1515","LU1993786604.SGD","LU1226287875.USD","SG9999004220.SGD","IE0008369823.USD","IE00B031HY20.USD","LU0315179316.USD","01093","IE00BZ08YR35.GBP","LU1328277881.USD","BK1521","BK1191","LU0067412154.USD","LU0501845795.SGD","IE0008368742.USD","LU2039709279.SGD","LU1951186391.HKD","LU0880133367.SGD","LU1960683339.HKD","LU1226287529.USD","LU1226287792.SGD","IE00B543WZ88.USD","EWH","LU1152091754.HKD","LU0326950275.SGD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637318651","title":"石药集团(01093)：乌司奴单抗注射液获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2637318651","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637318651?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:49","pubTimestamp":1779443362,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，集团开发的乌司奴单抗注射液（商品名：恩益克® ）已获得中国国家药品监督管理局批准上市。该产品是一种全人源Ig G1κ单克隆抗体，可与人白细胞介素IL -12和IL -23的p40蛋白亚单位以高亲和力 和特异性结合。IL -12 和IL -23 是天然产生的细胞因子，参与斑块状银屑病和克罗恩病炎症和免疫应答过程，在其发病机制中发挥核心作用。乌司奴单抗通过阻断与细胞表面受体链IL -12Rβ1的相互作用，破坏IL -12和IL -23介导的信号传导和细胞因子的级联反应，从而有效缓解疾病症状、持续改善病情，为患者带来长期临床获益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2039709279.SGD","LU0072913022.USD","LU0315179316.USD","IE00B031HY20.USD","IE0008369823.USD","LU1226287792.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU1152091168.USD","LU1226287875.USD","HK0000165453.HKD","BK1521","LU1226288253.USD","LU1328277881.USD","IE00BZ08YT58.USD","LU0067412154.USD","LU0501845795.SGD","LU1226287529.USD","LU1960683339.HKD","IE0008368742.USD","01093","LU0140636845.USD","IPOS","LU1813983027.USD","LU1993786604.SGD","SG9999004220.SGD","BK1191","LU0880133367.SGD","LU1807302812.USD","LU0314109678.HKD","BK1515","LU0326950275.SGD","LU1951186391.HKD","IE00B5MMRT66.SGD","LU1152091754.HKD","IE00B543WZ88.USD","LU1226288170.HKD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637539896","title":"大行评级丨瑞银：升石药集团评级至买入 估值尚未反映AI药物研发实力","url":"https://stock-news.laohu8.com/highlight/detail?id=2637539896","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637539896?lang=zh_cn&edition=full","pubTime":"2026-05-22 13:27","pubTimestamp":1779427630,"startTime":"0","endTime":"0","summary":"瑞银发表研报指，石药集团是领先医药企业中AI药物研发的先行者，按交易总价值计算，更是全球最大的AIDD平台对外授权方。该行认为，石药在AI等前沿技术的领先地位尚未完全反映在估值中。瑞银将石药评级由中性上调至买入，维持目标价10.9港元。瑞银指出，石药目前已达成4项与AIDD平台相关的授权或合作协议，累计交易总额达277亿美元，成为全球最大的AIDD平台授权方。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260522/32246407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["ARTY","AIPO","AGIX","CHAT","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122367326","title":"异动解读｜石药集团盘中上涨3.68%，布地奈德肠溶胶囊获批叠加多款创新药管线进展提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1122367326","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122367326?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:39","pubTimestamp":1779413956,"startTime":"0","endTime":"0","summary":"5月22日，石药集团盘中上涨3.68%，报7.82港元/股，成交额1.38亿港元。消息面上，公司近期迎来密集管线利好。5月21日，石药集团宣布其开发的布地奈德肠溶胶囊获得国家药品监督管理局药品注册批件，用于治疗具有疾病进展风险的原发性IgA肾病成人患者。此外，公司此前还获批创新药SYH2095片及国内首款体内CAR-T产品SYS6055注射液的中国临床试验许可，创新管线推进节奏加快，市场情绪有所修复。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637847473","title":"石药集团(01093)：布地奈德肠溶胶囊(4mg)获药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2637847473","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637847473?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:14","pubTimestamp":1779358471,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的布地奈德肠溶胶囊(该产品)已获得中华人民共和国国家药品监督管理局颁发的药品注册批件。布地奈德可抑制位于回肠派尔集合淋巴结中的黏膜B细胞的增生和其向浆细胞的分化，从而抑制半乳糖缺陷的IgA1抗体的产生。其通过减少体循环中的Gd-IgA1抗体和免疫复合物的形成，减少导致肾小球肾炎和肾功能下降的肾小球系膜区免疫复合物的沉积。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：布地奈德肠溶胶囊(4mg)获药品注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1951186391.HKD","LU0067412154.USD","LU0315179316.USD","LU2039709279.SGD","IE0008369823.USD","LU0314109678.HKD","LU0326950275.SGD","LU1226287875.USD","LU1328277881.USD","LU1960683339.HKD","LU1993786604.SGD","SG9999004220.SGD","BK1515","LU0140636845.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU0072913022.USD","BK1521","LU1152091168.USD","LU1152091754.HKD","LU0880133367.SGD","IE00B031HY20.USD","LU1226287529.USD","LU1226287792.SGD","LU1807302812.USD","BK1191","01093","LU1226288170.HKD","IE0008368742.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1813983027.USD","LU1008478684.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118756677","title":"石药集团布地奈德肠溶胶囊获中国国家药监局药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1118756677","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118756677?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:13","pubTimestamp":1779358392,"startTime":"0","endTime":"0","summary":"石药集团宣布，其布地奈德肠溶胶囊已成功获得中国国家药品监督管理局的药品注册批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU1226287792.SGD","IE00BZ08YR35.GBP","BK1521","LU1813983027.USD","LU0326950275.SGD","LU1993786604.SGD","LU1226287529.USD","LU1226288253.USD","LU0140636845.USD","LU0880133367.SGD","LU0072913022.USD","BK1191","IE00BZ08YS42.EUR","LU1226288170.HKD","LU1152091168.USD","IE00B031HY20.USD","LU1226287875.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU2039709279.SGD","01093","LU0315179316.USD","LU1960683339.HKD","LU1807302812.USD","IE00B543WZ88.USD","LU1152091754.HKD","LU1008478684.HKD","LU1328277881.USD","LU0067412154.USD","BK1515","HK0000165453.HKD","SG9999004220.SGD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","BK1583","01877","02616","CHAT","LU1152091168.USD","LU1303224171.USD","06978","06160","LU1152091754.HKD","159992","LU0348767384.USD","09688","01093","09995","01801","IE00B031HY20.USD","LU1226288170.HKD","LU1993786604.SGD","LU0572944931.SGD","SG9999002562.SGD","LU0140636845.USD","02142","LU0417516738.SGD","LU1960683339.HKD","AGIX","LU1719994722.HKD","LU0348827113.USD","LU0315179316.USD","LU0326950275.SGD","IE00BPRC5H50.USD","LU0072913022.USD","LU1880383366.USD","LU2097828631.EUR","LU0456846285.SGD","LU0456827905.SGD","LU0516422952.EUR","LU0634319403.HKD","LU0067412154.USD","02269","ARTY","06185","BK1161","09926","BK1589","LU0561508036.HKD","BK1588","LU0856984785.SGD","01177","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636589075","title":"石药集团(01093)：高选择性KAT6抑制剂(SYH2095片)在中国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636589075","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636589075?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:32","pubTimestamp":1779107546,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团与杭州英创医药科技有限公司合作开发的化学1类创新药SYH2095片已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品是一种新型的赖氨酸乙酰转移酶6抑制剂，属于一类表观遗传抗癌药。临床前研究表明，该产品对KAT6显示出高效且具选择性的抑制作用，可显著抑制肿瘤生长，具有良好的药代动力学特性与安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：高选择性KAT6抑制剂(SYH2095片)在中国获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0072913022.USD","LU1813983027.USD","SG9999004220.SGD","IE0008368742.USD","LU0501845795.SGD","LU1226288170.HKD","BK1191","LU1807302812.USD","LU1226287792.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","IE0008369823.USD","LU1008478684.HKD","LU1152091168.USD","01093","BK1521","IE00B543WZ88.USD","LU1960683339.HKD","LU1328277881.USD","IE00BZ08YS42.EUR","BK1515","LU1226287529.USD","LU0314109678.HKD","LU1993786604.SGD","LU0880133367.SGD","HK0000165453.HKD","IE00B031HY20.USD","LU2039709279.SGD","LU0067412154.USD","LU1152091754.HKD","LU0326950275.SGD","LU0140636845.USD","LU1226288253.USD","LU0315179316.USD","IE00BZ08YR35.GBP","LU1951186391.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","IE00B543WZ88.USD","09926","02269","01177","IE00BZ08YR35.GBP","01093","601066","LU0039217434.USD","LU0348827113.USD","LU1303224171.USD","IE00BZ08YT58.USD","159992","LU1152091168.USD","02616","BK1141","IE00B0JY6N72.USD","LU1242518857.USD","LU0561508036.HKD","LU0979878070.USD","06160","LU0516423174.USD","LU2097828557.USD","LU1242518931.SGD","LU0516422952.EUR","BK1574","LU0326950275.SGD","LU1152091754.HKD","09995","06978","01877","LU1688375341.USD","09688","BK1588","LU1969619763.USD","LU2399975544.HKD","BK1161","LU2097828474.EUR","LU2097828631.EUR","LU1226287875.USD","LU1993786604.SGD","LU0456827905.SGD","LU0588546209.SGD","02142","LU0359202008.SGD","LU0417516738.SGD","01801","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634217641","title":"业绩下滑的石药集团又遇高管离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2634217641","media":"国际金融报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634217641?lang=zh_cn&edition=full","pubTime":"2026-05-12 21:35","pubTimestamp":1778592900,"startTime":"0","endTime":"0","summary":"5月12日，多家媒体报道称，石药集团执行总裁、全球首席医学官黑永疆于近日正式离职，并在上海开启个人创业。天眼查数据显示，上海慧思博生物医药科技有限公司于2026年4月13日在青浦区成立，法定代表人为黑永疆。这家公司注册资本为500万元，经营范围涵盖技术服务、技术开发、自然科学研究和试验发展、医学研究和试验发展等多个领域，所属行业为科技推广和应用服务业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734818918.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734818918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B031HY20.USD","LU1226287875.USD","SG9999004220.SGD","LU1152091754.HKD","LU1226288253.USD","LU0501845795.SGD","LU1951186391.HKD","LU2039709279.SGD","LU0326950275.SGD","IE00B5MMRT66.SGD","IE0008369823.USD","LU0140636845.USD","LU1960683339.HKD","LU1008478684.HKD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU1807302812.USD","LU0315179316.USD","LU0314109678.HKD","LU0067412154.USD","LU1152091168.USD","BK1515","IE00BZ08YT58.USD","LU1226287529.USD","HK0000165453.HKD","01093","BK1191","LU1328277881.USD","BK1521","LU0880133367.SGD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1226287792.SGD","LU1993786604.SGD","LU1226288170.HKD","LU1813983027.USD","IE0008368742.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634584262","title":"黑永疆离开石药创业，医药老兵“第三阶段”想干什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634584262","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634584262?lang=zh_cn&edition=full","pubTime":"2026-05-12 14:10","pubTimestamp":1778566200,"startTime":"0","endTime":"0","summary":"5月6日，工信部刚刚公布了石药集团入选2025年数字化转型典型案例的消息。然而就在几天之后，这艘老牌航母刚刚完成“航母+AI”的华丽转身，正朝着创新药全球化全力调头之际，又一则重磅消息搅动了整个生物医药圈。　　市场消息显示，石药集团执行总裁、全球首席医学官黑永疆博士，已从石药集团正式离职，创立上海慧思博生物医药科技有限公司。　　企业信息显示，慧思博生物成立于2026年4月13日，注册资本500万元，位于上海青浦区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/2026-05-12/doc-inhxrmyk1526070.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/2026-05-12/doc-inhxrmyk1526070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1152091168.USD","LU1226287875.USD","09939","IE00B543WZ88.USD","LU1226287792.SGD","LU1226288170.HKD","BK1515","LU1807302812.USD","01093","IE0008369823.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1521","BK1191","LU0501845795.SGD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1960683339.HKD","BK1574","159938","LU2039709279.SGD","HK0000165453.HKD","LU0072913022.USD","LU1226287529.USD","161022","SG9999004220.SGD","LU0140636845.USD","LU0314109678.HKD","LU1993786604.SGD","LU1951186391.HKD","BK1161","LU0315179316.USD","IE0008368742.USD","LU0326950275.SGD","LU1008478684.HKD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1226288253.USD","LU1328277881.USD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634402954","title":"石药集团(01093)：SYS 6010于中国再次获纳入突破性治疗品种名单用于治疗局部晚期或转移性食管鳞状细胞癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2634402954","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634402954?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:43","pubTimestamp":1778492619,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团自主研发的SYS 6010近日再次获中国国家药品监督管理局纳入突破性治疗品种名单，拟定适应症为单药用于既往接受含铂化疗及免疫治疗失败的局部晚期或转移性食管鳞状细胞癌患者。此前，该产品针对EGFR突变耐药非小细胞肺癌适应症已于2025年1月获国家药监局纳入突破性治疗品种名单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：SYS 6010于中国再次获纳入突破性治疗品种名单用于治疗局部晚期或转移性食管鳞状细胞癌患者","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0314109678.HKD","LU0326950275.SGD","LU1152091168.USD","LU1328277881.USD","LU1226288170.HKD","LU0501845795.SGD","IE00BZ08YT58.USD","LU1993786604.SGD","HK0000165453.HKD","LU2039709279.SGD","LU1226287792.SGD","LU1226287875.USD","LU0067412154.USD","IE00B031HY20.USD","LU1813983027.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE0008369823.USD","BK1521","LU0880133367.SGD","LU1152091754.HKD","LU0072913022.USD","IE00BZ08YR35.GBP","01093","LU1960683339.HKD","IE00BZ08YS42.EUR","SG9999004220.SGD","BK1515","LU0315179316.USD","LU1226287529.USD","LU0140636845.USD","LU1951186391.HKD","IE0008368742.USD","LU1226288253.USD","LU1807302812.USD","BK1191","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634015154","title":"花旗：中国医疗保健行业基本面持续改善 首选药明康德(02359)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2634015154","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634015154?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:54","pubTimestamp":1778489665,"startTime":"0","endTime":"0","summary":"创新正获得回报，授权交易预付款及里程碑付款带动盈利，创新药销售加速，而CXO订单量更创下历史新高。展望未来，该行预期将有一系列短期催化剂，包括ASCO 2026年数据发布、授权交易势头持续、4月14日药品价格改革后续、CXO指引可能上调，以及市场整合加速利好医疗科技、服务及药房领导者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","BK4504","IE00B5MMRT66.SGD","LU0072461881.USD","BK1141","LU0098860793.USD","BK1515","BK1191","01801","IE0008369823.USD","LU2125154935.USD","02359","LU0314109678.HKD","LU1366192091.USD","LU1997244956.HKD","LU0310800965.SGD","LU2045819591.USD","LU2360032135.SGD","LU0516423174.USD","LU2417539215.USD","LU0359202008.SGD","01276","LU0326950275.SGD","LU2242644610.SGD","LU1719994722.HKD","01093","LU0455707207.USD","IE00B031HY20.USD","LU0980610538.SGD","LU0203347892.USD","IE00BZ08YT58.USD","LU0315179316.USD","LU0979878070.USD","LU1506573853.SGD","603259","02269","LU0516422366.SGD","LU1951186391.HKD","LU0572944931.SGD","LU1242518857.USD","LU1226288253.USD","LU1023057109.AUD","SG9999004220.SGD","LU1997245177.USD","LU0170899867.USD","LU1008478684.HKD","LU2488822045.USD","01672","LU0307460666.USD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161450093","title":"石药集团2026年4月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1161450093","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161450093?lang=zh_cn&edition=full","pubTime":"2026-05-04 17:17","pubTimestamp":1777886241,"startTime":"0","endTime":"0","summary":"2026年5月4日，石药集团有限公司（股票代码：01093）披露2026年4月股份变动月报表，报告期截至2026年4月30日。根据公告显示，报告期内公司法定及注册股本未发生变化，期末已发行普通股股数为11,522,451,732股，库存股份数目为0，期间无新增发行、回购或注销股本活动。\n在股份期权方面，根据公司于2015年12月9日生效的2015年购股权计划，截至4月末的股份期权总数为1,300,000股，本月内无新股发行或库存股转让，期末持有的股份期权数量与上月份相同。公司重申，当前公众持股量符合香港联交所上市规则要求。本次月报由公司秘书罗泰安签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631229636","title":"汇添富基金增持石药集团(01093)296.6万股 每股作价约8.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631229636","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631229636?lang=zh_cn&edition=full","pubTime":"2026-04-30 19:10","pubTimestamp":1777547452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，4月28日，汇添富基金管理股份有限公司增持石药集团(01093)296.6万股，每股作价8.4977港元，总金额约为2520.42万港元。增持后最新持股数目约为5.79亿股，持股比例为5.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1951186391.HKD","LU0067412154.USD","LU0315179316.USD","LU2039709279.SGD","IE0008369823.USD","LU0314109678.HKD","LU0326950275.SGD","LU1226287875.USD","LU1328277881.USD","LU1960683339.HKD","LU1993786604.SGD","SG9999004220.SGD","BK1515","LU0140636845.USD","EWH","IE00BZ08YR35.GBP","LU0501845795.SGD","LU0072913022.USD","BK1521","LU1152091168.USD","LU1152091754.HKD","LU0880133367.SGD","IE00B031HY20.USD","LU1226287529.USD","LU1226287792.SGD","LU1807302812.USD","BK1191","01093","LU1226288170.HKD","IE0008368742.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU1813983027.USD","LU1008478684.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631799055","title":"石药集团一项创新研究成果在ACS Org. Process Res. Dev.发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2631799055","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631799055?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:47","pubTimestamp":1777510064,"startTime":"0","endTime":"0","summary":"【石药集团一项创新研究成果在ACS Org. Process Res. Dev.发表】据石药集团消息，近日，由石药集团研发的基于在线红外光谱技术用于寡核苷酸固相合成脱保护工艺优化的研究成果以研究论文（Article）形式发表在国际著名化学期刊ACS旗下Org. Process Res. Dev.杂志。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604303725558663.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604303725558663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1226287529.USD","BK1191","LU0315179316.USD","LU1813983027.USD","LU1008478684.HKD","LU1807302812.USD","LU0067412154.USD","IE00B031HY20.USD","LU1226288170.HKD","LU1226288253.USD","BK1521","01093","LU1226287875.USD","LU1328277881.USD","IE00BZ08YT58.USD","LU0140636845.USD","LU1226287792.SGD","LU0501845795.SGD","HK0000165453.HKD","LU0314109678.HKD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","SG9999004220.SGD","IE0008368742.USD","LU1993786604.SGD","LU2039709279.SGD","BK1515","IE00BZ08YS42.EUR","LU1951186391.HKD","LU1960683339.HKD","LU1152091754.HKD","IE00B543WZ88.USD","IE0008369823.USD","LU0880133367.SGD","LU0072913022.USD","LU1152091168.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631518822","title":"石药集团(01093)：注射用两性霉素B脂质体(HC1507G2) 在欧洲获上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631518822","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631518822?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:05","pubTimestamp":1777460747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团自主开发的注射用两性霉素B脂质体(该产品)在欧盟的上市申请已获批准。两性霉素B是大环多烯类抗真菌抗生素，通过与真菌细胞膜上的甾醇结合，改变细胞膜通透性，发挥抗真菌作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1813983027.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1960683339.HKD","LU0880133367.SGD","BK1515","BK1191","LU0067412154.USD","IE0008369823.USD","LU0314109678.HKD","HK0000165453.HKD","LU1152091754.HKD","LU0326950275.SGD","LU1226288170.HKD","LU2039709279.SGD","IPOS","01093","IE00B031HY20.USD","LU0140636845.USD","IE00BZ08YT58.USD","BK1521","IE00BZ08YS42.EUR","LU0315179316.USD","LU1226287529.USD","LU1807302812.USD","LU1993786604.SGD","IE0008368742.USD","LU1951186391.HKD","LU1152091168.USD","LU1226288253.USD","LU0072913022.USD","LU1226287875.USD","SG9999004220.SGD","IE00BZ08YR35.GBP","LU1008478684.HKD","LU0501845795.SGD","LU1328277881.USD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631590776","title":"石药集团(01093)开发的抗体偶联药物SYS6051在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631590776","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631590776?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:02","pubTimestamp":1777460576,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)公布，该集团开发的抗体偶联药物SYS6051的试验性新药(IND)申请已获美国食品药品监督管理局(FDA)批准，可在美国开展临床试验。该产品亦已于2026年4月获得中华人民共和国国家药品监督管理局批准，可以在中国开展临床试验。该产品为一款靶向人组织因子(TF)的抗体偶联药物，可与肿瘤细胞表面的组织因子结合，通过内吞作用进入细胞并释放毒素，达到杀伤肿瘤细胞的作用。本次获批的适应症为晚期实体瘤。临床前研究显示，该产品对多种癌症均有较好的抗肿瘤作用，有望在后续临床试验中展现出良好的治疗效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)开发的抗体偶联药物SYS6051在美国获临床试验批准","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU1226288253.USD","LU0315179316.USD","LU1226288170.HKD","LU1960683339.HKD","IE00BZ08YR35.GBP","LU1328277881.USD","LU0072913022.USD","LU0067412154.USD","IE00B543WZ88.USD","LU0326950275.SGD","LU1008478684.HKD","HK0000165453.HKD","IE0008368742.USD","LU0314109678.HKD","LU0140636845.USD","BK1515","01093","LU1152091168.USD","LU1226287529.USD","LU1813983027.USD","LU2039709279.SGD","IE00B5MMRT66.SGD","BK1521","IE00B031HY20.USD","LU0880133367.SGD","SG9999004220.SGD","LU0501845795.SGD","LU1226287792.SGD","IE00BZ08YT58.USD","LU1993786604.SGD","IE0008369823.USD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU1152091754.HKD","LU1807302812.USD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101195654","title":"石药集团拟回购不超过已发行股份10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101195654","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101195654?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:43","pubTimestamp":1777376603,"startTime":"0","endTime":"0","summary":"石药集团于4月29日公告，董事会拟于2026年5月28日召开的股东周年大会上提请授予回购公司股份的一般性授权，最高回购规模不超过公司于该决议案通过当日已发行股份总数的10%。根据公告，石药集团当前已发行股份数为11,522,451,732股，此次购回权限上限对应约1,152,245,173股。此外，石药集团拟在同日举行的股东周年大会上提议续聘核数师，并就年度财务报表、董事薪酬等事项作出决议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团拟回购不超过已发行股份10%","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191267081","title":"石药集团2025年收入下滑10.4%至260.06亿元，净利同比降10.3%并聚焦创新药布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1191267081","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191267081?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:39","pubTimestamp":1777376372,"startTime":"0","endTime":"0","summary":"石药集团在其2025年度报告中披露，期内实现总收入人民币260.06亿元，较2024年的290.09亿元下降10.4%。按业务板块划分，成药业务收入为人民币205.84亿元，同比下降13.3%；原料产品业务收入36.57亿元，同比增长2.1%；功能食品及其他业务收入17.65亿元，同比增长4.5%。利润方面，股东应占溢利约人民币38.82亿元，较上年度43.28亿元下降10.3%。从财务结构来看，截至2025年12月31日，集团总资产为约人民币466.98亿元，较上年增长约5.2%；流动比率为2.21倍，总体偿债能力良好。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"石药集团2025年收入下滑10.4%至260.06亿元，净利同比降10.3%并聚焦创新药布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.1231},{"period":"3month","weight":-0.269},{"period":"6month","weight":0.042},{"period":"1year","weight":0.2204},{"period":"ytd","weight":-0.0878}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0153},{"period":"1year","weight":0.0876},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门：成药部门、抗生素（中间体及原料药）部门、维生素C（原料药）部门及咖啡因及其他（原料药）部门，分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094687},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017323},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057765},{"month":5,"riseRate":0.59375,"avgChangeRate":0.043276},{"month":6,"riseRate":0.322581,"avgChangeRate":0.003636},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013271}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}